Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estrone | Estrone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estradiol | Estradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Mestranol | Mestranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estriol | Estriol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Tibolone | Tibolone may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Zeranol | Zeranol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Equol | Equol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Promestriene | Promestriene may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Formononetin | Formononetin may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Estetrol | Estetrol may increase the thrombogenic activities of Digoxin Immune Fab (Ovine). |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Digoxin Immune Fab (Ovine). |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Digoxin Immune Fab (Ovine). |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Digoxin Immune Fab (Ovine). |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Digoxin Immune Fab (Ovine). |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Digoxin Immune Fab (Ovine). |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Digoxin Immune Fab (Ovine). |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Digoxin Immune Fab (Ovine). |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Digoxin Immune Fab (Ovine). |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Digoxin Immune Fab (Ovine). |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Digoxin Immune Fab (Ovine). |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Digoxin Immune Fab (Ovine). |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Digoxin Immune Fab (Ovine). |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ibritumomab tiuxetan. |
| Tositumomab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tositumomab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Alemtuzumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Capromab pendetide. |
| Efalizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Antithymocyte immunoglobulin (rabbit). |
| Natalizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Natalizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Palivizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Daclizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bevacizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Technetium Tc-99m arcitumomab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eculizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Panitumumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ranibizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Galiximab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Pexelizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Afelimomab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Epratuzumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bectumomab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Oregovomab. |
| IGN311 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IGN311. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Adecatumumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Labetuzumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Matuzumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Canakinumab. |